Mizuho analyst Bradley Bowers initiated coverage of Guardant Health (GH) with an Outperform rating and $55 price target The firm is bullish on ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Barclays lowered the firm’s price target on Guardant Health (GH) to $55 from $60 and keeps an Overweight rating on the shares as part of a Q1 ...

As of April 2, 2025, the average one-year price target for Guardant Health is $56.46/share. The forecasts range from a low of $20.20 to a high of $68.25. The average price target represents an ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market ...

American Century Companies Inc. reduced its stake in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and ...

With U.S. stock markets set to open in two hours, Guardant Health Inc. (GH) was up 9.1% in pre-market trading, and Brookfield Wealth Solutions Ltd. (BNT) was up 8.4%.

PALO ALTO, Calif., March 25, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of Guardant Health (BMV:GH) with a Outperform recommendation. What is the Fund Sentiment? There are 763 funds or institutions ...